Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Single-arm, Multicentre Real-world Observational Study of TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer

NCT05993702 is registered in ClinicalTrials.gov with China Medical University, China as lead sponsor.

NCT NCT05993702
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05993702 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Single-arm, Multicentre Real-world Observational Study of TAS-102 in Combination With Regorafenib or Fruquintinib for Third-line and Above Advanced Colorectal Cancer
Lead sponsor
China Medical University, China
Phase
Observational
Overall status
Unknown status
Start date
September 1, 2023
Completion date
June 1, 2025
Enrollment
45 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

fruquintinib, gastrointestinal tumours, regorafenib, tas 102